The estimated Net Worth of Wise Young is at least $11.4 Тысяча dollars as of 8 December 2006. Dr Young owns over 641 units of Acorda Therapeutics Inc stock worth over $11,423 and over the last 18 years he sold ACOR stock worth over $0.
Dr has made over 1 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 641 units of ACOR stock worth $1,000 on 8 December 2006.
The largest trade he's ever made was exercising 641 units of Acorda Therapeutics Inc stock on 8 December 2006 worth over $1,000. On average, Dr trades about 107 units every 0 days since 2006. As of 8 December 2006 he still owns at least 17,307 units of Acorda Therapeutics Inc stock.
You can see the complete history of Dr Young stock trades at the bottom of the page.
Dr. Wise Young M.D., Ph.D. is the Special Scientific Advisor at Acorda Therapeutics Inc.
Dr D is 70, he's been the Special Scientific Advisor of Acorda Therapeutics Inc since . There are 2 older and 14 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
Wise's mailing address filed with the SEC is 15 SKYLINE DRIVE, , HAWTHORNE, NY, 10532.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith и Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: